All News Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
980.2 ^USD	+1.06%		-0.49%	+11.60%

May. 31	EMA backs approving Sanofi's Dupixent for 'smoker's lungs', FDA extends review	RE
May. 31	Sanofi, Regeneron's Dupixent Receives Recommendation for Approval From European Medicines Agency Committee	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

EMA backs approving Sanofi's Dupixent for 'smoker's lungs', FDA extends review	May. 31	RE
Sanofi, Regeneron's Dupixent Receives Recommendation for Approval From European Medicines Agency Committee	May. 31	MT
Regeneron Pharmaceuticals, Sanofi Say Dupixent FDA Application Decision Delayed by 3 Months	May. 31	MT
Sanofi's Dupixent Drug Review Date Extended by Three Months in the U.S.	May. 31	DJ
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD	May. 31	GL
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD	May. 31	AQ
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation	May. 31	GL
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation	May. 31	AQ
Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® for the Treatment of COPD Patients with Type 2 Inflammation	May. 31	CI
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN	May. 30	PR
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,142,536, According to a Recent SEC Filing	May. 29	MT
Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors	May. 29	PR
Regeneron Pharmaceuticals Says GN7075 Plus Libtayo Shows Anti-Tumor Responses in Microsatellite Stable Colorectal Cancer	May. 23	MT
Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO	May. 23	GL
Regeneron Pharmaceuticals, Inc. Announces Positive New Results from an Ongoing Phase 1/2 Trial Evaluating its First-in-Class Costimulatory Bispecific Antibody, REGN7075	May. 23	CI
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN	May. 22	PR
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,855,489, According to a Recent SEC Filing	May. 22	MT
Regeneron, Sanofi Disclose Positive Results for Lung Disease Treatment Candidate	May. 20	MT
Jefferies Raises Regeneron Pharmaceuticals' Price Target to $1,125 From $1,115	May. 20	MT
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine	May. 20	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

All News

Filters